HRP20250334T1 - Heterociklički spojevi za uporabu u liječenju raka - Google Patents

Heterociklički spojevi za uporabu u liječenju raka Download PDF

Info

Publication number
HRP20250334T1
HRP20250334T1 HRP20250334TT HRP20250334T HRP20250334T1 HR P20250334 T1 HRP20250334 T1 HR P20250334T1 HR P20250334T T HRP20250334T T HR P20250334TT HR P20250334 T HRP20250334 T HR P20250334T HR P20250334 T1 HRP20250334 T1 HR P20250334T1
Authority
HR
Croatia
Prior art keywords
compound
formula
cancer
treatment
heterocyclic compounds
Prior art date
Application number
HRP20250334TT
Other languages
English (en)
Croatian (hr)
Inventor
Owen Davis
Robert Heald
Martin Stockley
Harry Finch
Sam MANN
Original Assignee
Artios Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artios Pharma Limited filed Critical Artios Pharma Limited
Publication of HRP20250334T1 publication Critical patent/HRP20250334T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20250334TT 2021-10-21 2022-10-21 Heterociklički spojevi za uporabu u liječenju raka HRP20250334T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2115156.8A GB202115156D0 (en) 2021-10-21 2021-10-21 Novel compounds
EP22797829.3A EP4419526B1 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer
PCT/GB2022/052690 WO2023067356A1 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
HRP20250334T1 true HRP20250334T1 (hr) 2025-06-06

Family

ID=78805918

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20250334TT HRP20250334T1 (hr) 2021-10-21 2022-10-21 Heterociklički spojevi za uporabu u liječenju raka

Country Status (24)

Country Link
US (1) US20240425511A1 (https=)
EP (2) EP4419526B1 (https=)
JP (2) JP2024539132A (https=)
KR (1) KR20240099274A (https=)
CN (2) CN119053600A (https=)
AR (1) AR127431A1 (https=)
AU (1) AU2022374050A1 (https=)
CA (1) CA3233255A1 (https=)
DK (1) DK4419526T3 (https=)
ES (1) ES3008687T3 (https=)
FI (1) FI4419526T3 (https=)
GB (1) GB202115156D0 (https=)
HR (1) HRP20250334T1 (https=)
HU (1) HUE070568T2 (https=)
IL (1) IL311922A (https=)
LT (1) LT4419526T (https=)
MX (1) MX2024004874A (https=)
PL (1) PL4419526T3 (https=)
PT (1) PT4419526T (https=)
RS (1) RS66620B1 (https=)
SI (1) SI4419526T1 (https=)
SM (1) SMT202500123T1 (https=)
TW (1) TW202334150A (https=)
WO (2) WO2023067355A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025077896A1 (zh) * 2023-10-12 2025-04-17 上海湃隆生物科技有限公司 一种DNA聚合酶theta抑制剂及其应用
CN118084767B (zh) * 2024-04-02 2025-06-17 康龙化成手性医药技术(宁波)有限公司 一种外型-6-氟甲基-3-氮杂双环[3,1,0]己烷盐酸盐及其衍生物的合成方法
WO2025214463A1 (zh) * 2024-04-13 2025-10-16 正大天晴药业集团股份有限公司 含有三并环结构的化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062754A1 (en) 2015-10-07 2017-04-13 New York University Compositions and methods for enhancing crispr activity by polq inhibition
US12358886B2 (en) * 2019-08-09 2025-07-15 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer

Also Published As

Publication number Publication date
PL4419526T3 (pl) 2025-04-22
SMT202500123T1 (it) 2025-05-12
LT4419526T (lt) 2025-03-25
EP4419527A1 (en) 2024-08-28
US20240425511A1 (en) 2024-12-26
JP2024542949A (ja) 2024-11-19
DK4419526T3 (da) 2025-02-17
EP4419526A1 (en) 2024-08-28
ES3008687T3 (en) 2025-03-24
FI4419526T3 (fi) 2025-02-13
CA3233255A1 (en) 2023-04-27
PT4419526T (pt) 2025-02-03
RS66620B1 (sr) 2025-04-30
WO2023067355A1 (en) 2023-04-27
EP4419526B1 (en) 2024-12-25
CN119053600A (zh) 2024-11-29
IL311922A (en) 2024-06-01
JP2024539132A (ja) 2024-10-28
CN118234728A (zh) 2024-06-21
KR20240099274A (ko) 2024-06-28
GB202115156D0 (en) 2021-12-08
WO2023067356A1 (en) 2023-04-27
SI4419526T1 (sl) 2025-05-30
AU2022374050A1 (en) 2024-05-02
AR127431A1 (es) 2024-01-24
HUE070568T2 (hu) 2025-06-28
TW202334150A (zh) 2023-09-01
MX2024004874A (es) 2024-05-06

Similar Documents

Publication Publication Date Title
HRP20250334T1 (hr) Heterociklički spojevi za uporabu u liječenju raka
CN114599361B (zh) Prmt5抑制剂的药物组合物
JP5911638B2 (ja) ベンゾチアゾール−6−イル酢酸誘導体およびhiv感染を処置するためのそれらの使用
FI3986897T3 (fi) Egfr-estäjä syövän hoitoon
ES2753966T3 (es) Inhibidores de replicación viral
ES2620612T3 (es) Derivados de sulfóxidos y sulfonas de piridinilo y pirimidinilo
ZA202001390B (en) Crystalline forms
HRP20200624T1 (hr) Derivati 2-(2,4,5-supstituiranog-anilino)pirimidina kao modulatori egfr korisni za liječenje raka
HRP20211642T1 (hr) Derivati benzizotiazola, izotiazolo[3,4-b]piridina, kinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao inhibitori kras g12c za liječenje raka pluća, gušterače ili kolorektalnog karcinoma
JP2017531039A5 (https=)
EA202191498A1 (ru) 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
JP2020504747A5 (https=)
EP1202746A1 (en) Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
AU2008236562A1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
KR20010050223A (ko) Crf 길항제 및 관련 조성물의 용도
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
MX2020010675A (es) Derivados de pirazolo-triazina y/o pirazolo-pirimidina como inhibidor selectivo de cinasa dependiente de ciclina.
FI3805222T3 (fi) 7-bentsyyli-4-(2-metyylibentsyyli)-2,4,6,7,8,9-heksahydroimidatso[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-onijohdannaisia, niiden suoloja ja niiden käyttö hoidossa
JP2018501315A5 (https=)
MX380989B (es) Composición farmacéutica que contiene un inhibidor de janus quinasa o una sal farmacéuticamente aceptable del mismo.
FI3865484T3 (fi) Pde9:n estäjä, jossa on imidatsopyratsinonirunko, perifeeristen sairauksien hoitoon
JP2024542949A5 (https=)
JP2017501983A5 (https=)
FI3478284T3 (fi) Yhdisteitä ja koostumuksia syövän hoitoon